-
Document de presse | 2021.05.27
COVID-19, one year on: persistence of protective antibodies and significantly reduced risk of reinfection
A study conducted by the University Hospital of Strasbourg (HUS) in collaboration with the Institut Pasteur, published as a preprint on medRxiv, has led to a significant advance in knowledge about COVID-19.In connection with the SeroCoV-HUS study led by Professor Samira Fafi-Kremer (University Hospital of Strasbourg (HUS) – University of Strasbourg – INSERM UMR1109), the team at Strasbourg...
-
News | 2023.10.06
Diphtheria: a novel bacterial species identified
A team from the Institut Pasteur has described a novel bacterial species in the Corynebacteriaceae family, capable of causing diphtheria. The identification of this distinct species will pave the way for improved surveillance and disease prevention.
-
Article | 2016.12.20
Parasites and Insect Vectors
Parasitic diseases are all too often neglected. However, they affect close to 3 billion people in the world. Biomedical research is therefore at the heart of global public health challenges, and the mission of the scientists in this department is to tackle the ongoing need for better prevention, control and treatment of these parasitic diseases.
-
News | 2020.07.20
i-Lab 2020 competition: two winners from the Institut Pasteur, one awarded a Grand Prix
On July 16, the i-Lab 2020 innovation competition unveiled the names of 73 winners, which this year included the D4Zin (Grand Prix) and AVATAR MEDICAL projects, both based on research carried out at the Institut Pasteur and supported by the Pasteur Microbes and Health Carnot Institute.Sponsored by the French Ministry of Higher Education, Research and Innovation and organized in partnership with...
-
Document de presse | 2021.12.23
COVID-19 – Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the Omicron variant is more transmissible than the currently dominant virus (the Delta variant). It is capable of spreading to individuals who have received...
-
Fiche maladie | 2018.12.05
Cholera
Cholera is an epidemic acute diarrheal disease that only affects humans and is caused by serogroup O1 (and in rare cases O139) of the Vibrio cholerae bacterium. Although this infection is sometimes caused by direct contact with infected individuals (e.g. through unwashed hands, last offices, etc.), it is more commonly attributable to the ingestion of water or food contaminated with the feces of...
-
Fiche maladie | 2020.09.23
Meningococcal meningitis
Meningitis is an infection of the spinal cord and the brain membranes – or meninges –, caused by several types of virus, bacteria and fungi. Meningococci (another name for Neisseria meningitidis bacteria) are the main cause of acute meningitis. Despite treatment, meningococcal infections have a high mortality rate (10%) and considerable epidemic potential.
-
Fiche maladie | 2019.10.16
Chikungunya
Chikungunya is a viral disease transmitted to humans by the bite of Aedes albopictus and Aedes aegypti mosquitoes. Although rarely fatal, chikungunya can cause significant pain and debilitating symptoms that affect patients' quality of life. Existing treatments are solely symptomatic. In France, the current conditions in 80% of départements are conducive to the emergence of chikungunya.
-
News | 2025.10.03
COVID-19: how worried should we be about the Frankenstein variant?
As long as the SARS-CoV-2 virus is still circulating, there is a possibility of new, less intense but persistent waves in France and around the world. In September 2025, the Frankenstein variant, a sub-variant of Omicron with low virulence, was widely observed. So what is the current situation with COVID-19 in France? Interview with Olivier Schwartz, Head of the Virus and Immunity Unit at the...
-
Document de presse | 2015.02.02
Moderna and Institut Pasteur Sign Strategic Research Collaboration
Research partnership will advance the development of mRNA vaccines and passive immunity therapies for infectious diseases. Press releaseCAMBRIDGE, Mass. (USA) and Paris (France), Feb. 3rd, 2015 Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ and the Institut Pasteur, a recognized public benefit organization with three core missions -...